grant
Development of Targeted Antipseudomonal Bactericidal Prodrugs
NIHUS FederalResearch GrantFY2026AccelerationAddressAirway infectionsAnti-Bacterial AgentsAnti-Rejection TherapyAntibiotic AgentsAntibiotic DrugsAntibiotic ResistanceAntibioticsAntibodiesAntibody-drug conjugatesBacteremiaBacteria resistanceBacteria resistantBacterial InfectionsBacterial resistantBacteriolysisBindingBioavailabilityBiological AvailabilityBiological MarkersBlood CirculationBloodstreamCancer TreatmentCell BodyCell DeathCell membraneCellsCenters for Disease ControlCenters for Disease Control and PreventionCenters for Disease Control and Prevention (U.S.)Chronic lung diseaseClinicalClinical ResearchClinical StudyCytoplasmic MembraneDevelopmentDose LimitingDrug PrecursorsDrugsEnzyme GeneEnzymesFDA approvedFRETFatality rateFluorescence Resonance Energy TransferFrequenciesFörster Resonance Energy TransferGenesGenetics-MutagenesisGoalsGram-Negative BacteriaHospital AdmissionHospitalizationHost FactorHost Factor ProteinImmuneImmunesImmunosuppressive TherapyIn VitroInfectionInjury to KidneyIntegration Host FactorsIntermediary MetabolismIntravenousKidneyKidney Urinary SystemKineticsLaboratoriesLeadLibrariesLipidsLung infectionsLytotoxicityMMPsMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMarketingMatrix MetalloproteinasesMeasuresMedicationMetabolic ProcessesMetabolismMiceMice MammalsMiscellaneous AntibioticModelingMolecular InteractionMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMurineMusMutagenesisMutagenesis Molecular BiologyNephrotoxicNeutropeniaP aeruginosaP. aeruginosaP. aeruginosa infectionPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPb elementPeptidesPharmaceutical PreparationsPharmacologic ActionsPhysiologic AvailabilityPlasma MembranePneumoniaPolymersPolymyxin BPolymyxin B resistancePolymyxin B resistantPolymyxin ResistancePolymyxin ResistantPolymyxinsPro-DrugsProdrugsPropertyProteinsPseudomonas aeruginosaPseudomonas aeruginosa infectionPseudomonas pyocyaneaPublic HealthResearchResistanceResistance developmentResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistance to antibioticsResistant developmentResistant to Multiple DrugResistant to antibioticsResistant to multi-drugResistant to multidrugRespiratory InfectionsRespiratory Tract InfectionsSepsisSiteSourceSurfaceSurgical Wound InfectionTherapeutic immunosuppressionThrombaseThrombinTimeToxic effectToxicitiesUnited States Centers for Disease ControlUnited States Centers for Disease Control and PreventionUrinary tract infectionUrinary tract infectious diseaseVariantVariationVirulenceWorld Health Organizationabsorptionanti-bacterialanti-cancer therapyanti-microbialanti-microbial peptideanti-microbial resistant infectionantibiotic drug resistanceantibiotic resistantantimicrobialantimicrobial resistant infectionartificial immunosuppressionbacteraemiabacteria infectionbacterial bloodstream infectionbacterial diseasebacterial infection in the bloodstreambacterial resistancebactericidalbactericidebio-markersbiologic markerbiomarkerblood infectionbloodstream infectioncancer therapycancer-directed therapychemotherapychronic pulmonary diseaseclinical relevanceclinically relevantco-morbidco-morbiditycombatcomorbiditycytotoxicitydesigndesigningdeveloping resistancedevelopmentaldrug clearancedrug/agentfibrinogenaseheavy metal Pbheavy metal leadimmunosuppression therapyimprovedin vivoinfected with P. aeruginosainfected with Pseudomonas aeruginosainfection in the bloodinfection of the bloodkidney injurykidney toxicitymouse modelmulti-drug resistantmultidrug resistantmurine modelnecrocytosisnephrotoxicitynovelpathogenpatient oriented outcomesplasmalemmapolymerpolymericpulmonary infectionsrenalrenal injuryresidenceresidential buildingresidential siteresistance strainresistance to Bacteriaresistance to Bacterialresistance to polymyxinresistantresistant strainresistant to Bacteriaresistant to Bacterialresistant to polymyxinsmall moleculesuccesssurgical site infectionurinary infection
Description preview
Bloodstream infections (BSI) caused by Pseudomonas aeruginosa have a high fatality rate. They often arise in
patients suffering from pneumonia, urinary tract infections, surgical site infections, or patients with severe
underlying conditions, including immunosuppression or chemotherapy-induced neutropenia. Systemic P.
aeruginosa is particularly…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click